{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:43:59Z","timestamp":1765889039918},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Surg Oncol"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s13193-022-01691-8","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T12:03:47Z","timestamp":1672920227000},"page":"181-188","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["High-Risk Peritoneal Mesothelioma: Does Metronomic Chemotherapy Have a Role?"],"prefix":"10.1007","volume":"14","author":[{"given":"Praveen","family":"Kammar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niharika","family":"Garach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditi","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay","family":"Anam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vashisth","family":"Maniar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adwaita","family":"Gore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanket","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,5]]},"reference":[{"issue":"15","key":"1691_CR1","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1016\/j.ejca.2013.05.027","volume":"49","author":"D Baratti","year":"1990","unstructured":"Baratti D, Kusamura S, Cabras AD, Bertulli R, Hutanu I, Deraco M (1990) 2013) Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC. Eur J Cancer Oxf Engl 49(15):3140\u20138","journal-title":"Eur J Cancer Oxf Engl"},{"issue":"4","key":"1691_CR2","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1245\/s10434-012-2845-x","volume":"20","author":"M Deraco","year":"2013","unstructured":"Deraco M, Baratti D, Hutanu I, Bertuli R, Kusamura S (2013) The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 20(4):1093\u20131100","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"1691_CR3","first-page":"1228","volume":"43","author":"PH Sugarbaker","year":"2017","unstructured":"Sugarbaker PH, Chang D (2017) Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 43(7):1228\u20131235","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"issue":"36","key":"1691_CR4","doi-asserted-by":"publisher","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","volume":"27","author":"TD Yan","year":"2009","unstructured":"Yan TD, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O et al (2009) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 27(36):6237\u20136242","journal-title":"J Clin Oncol"},{"issue":"3","key":"1691_CR5","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1245\/ASO.2006.05.041","volume":"13","author":"C Brigand","year":"2006","unstructured":"Brigand C, Monneuse O, Mohamed F, Sayag-Beaujard AC, Isaac S, Gilly FN et al (2006) Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. Ann Surg Oncol 13(3):405\u2013412","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"1691_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/annonc\/mdf013","volume":"13","author":"M Colleoni","year":"2002","unstructured":"Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nol\u00e8 F et al (2002) Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol Off J Eur Soc Med Oncol 13(1):73\u201380","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"2","key":"1691_CR7","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1093\/annonc\/mdj066","volume":"17","author":"M Colleoni","year":"2006","unstructured":"Colleoni M, Orlando L, Sanna G, Rocca A, Maisonneuve P, Peruzzotti G et al (2006) Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol Off J Eur Soc Med Oncol 17(2):232\u2013238","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"6","key":"1691_CR8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/1471-2407-6-225","volume":"15","author":"L Orlando","year":"2006","unstructured":"Orlando L, Cardillo A, Ghisini R, Rocca A, Balduzzi A, Torrisi R et al (2006) Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer 15(6):225","journal-title":"BMC Cancer"},{"issue":"8","key":"1691_CR9","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1097\/01.cad.0000224454.46824.fc","volume":"17","author":"L Orlando","year":"2006","unstructured":"Orlando L, Cardillo A, Rocca A, Balduzzi A, Ghisini R, Peruzzotti G et al (2006) Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anticancer Drugs 17(8):961\u2013967","journal-title":"Anticancer Drugs"},{"issue":"22","key":"1691_CR10","doi-asserted-by":"publisher","first-page":"3623","DOI":"10.1200\/JCO.2005.04.5773","volume":"24","author":"A Bottini","year":"2006","unstructured":"Bottini A, Generali D, Brizzi MP, Fox SB, Bersiga A, Bonardi S et al (2006) Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol Off J Am Soc Clin Oncol 24(22):3623\u20133628","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"1691_CR11","first-page":"133","volume":"16","author":"P Correale","year":"2006","unstructured":"Correale P, Cerretani D, Remondo C, Martellucci I, Marsili S, La Placa M et al (2006) A novel metronomic chemotherapy regimen of weekly platinum and daily oral etoposide in high-risk non-small cell lung cancer patients. Oncol Rep 16(1):133\u2013140","journal-title":"Oncol Rep"},{"issue":"7","key":"1691_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/1471-2407-7-65","volume":"15","author":"R Samaritani","year":"2007","unstructured":"Samaritani R, Corrado G, Vizza E, Sbiroli C (2007) Cyclophosphamide, \u201cmetronomic\u201d chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer. BMC Cancer 15(7):65","journal-title":"BMC Cancer"},{"issue":"1","key":"1691_CR13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","volume":"26","author":"AA Garcia","year":"2008","unstructured":"Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L et al (2008) Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol Off J Am Soc Clin Oncol 26(1):76\u201382","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"4C","key":"1691_CR14","first-page":"2605","volume":"27","author":"Y Ogata","year":"2007","unstructured":"Ogata Y, Sasatomi T, Mori S, Matono K, Ishibashi N, Akagi Y et al (2007) Significance of thymidine phosphorylase in metronomic chemotherapy using CPT-11 and doxifluridine for advanced colorectal carcinoma. Anticancer Res 27(4C):2605\u20132611","journal-title":"Anticancer Res"},{"issue":"5","key":"1691_CR15","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1593\/tlo.13481","volume":"6","author":"T Torimura","year":"2013","unstructured":"Torimura T, Iwamoto H, Nakamura T, Koga H, Ueno T, Kerbel RS et al (2013) Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma. Transl Oncol 6(5):511\u2013519","journal-title":"Transl Oncol"},{"key":"1691_CR16","doi-asserted-by":"crossref","unstructured":"John G Edwards 1, Daniel E B Swinson , J Louise Jones , Salli Muller , David A Waller , Kenneth J O\u2019Byrne ( 2003) Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma. Chest 124 5 1916\u20131923 11","DOI":"10.1378\/chest.124.5.1916"},{"issue":"5","key":"1691_CR17","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/ijc.10996","volume":"104","author":"R Masood","year":"2003","unstructured":"Masood R, Kundra A, Zhu S, Xia G, Scalia P, Smith DL et al (2003) Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. Int J Cancer 104(5):603\u2013610","journal-title":"Int J Cancer"},{"issue":"6","key":"1691_CR18","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1054\/bjoc.2001.1997","volume":"85","author":"JG Edwards","year":"2001","unstructured":"Edwards JG, Cox G, Andi A, Jones JL, Walker RA, Waller DA et al (2001) Angiogenesis is an independent prognostic factor in malignant mesothelioma. Br J Cancer 85(6):863\u2013868","journal-title":"Br J Cancer"},{"issue":"5","key":"1691_CR19","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1378\/chest.128.5.3382","volume":"128","author":"F Demirag","year":"2005","unstructured":"Demirag F, Unsal E, Yilmaz A, Caglar A (2005) Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma. Chest. 128(5):3382\u20137","journal-title":"Chest."},{"issue":"4","key":"1691_CR20","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1136\/thx.2007.085241","volume":"63","author":"H Kothmaier","year":"2008","unstructured":"Kothmaier H, Quehenberger F, Halbwedl I, Morbini P, Demirag F, Zeren H et al (2008) EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors. Thorax 63(4):345\u2013351","journal-title":"Thorax"},{"issue":"4","key":"1691_CR21","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/path.824","volume":"193","author":"L Strizzi","year":"2001","unstructured":"Strizzi L, Catalano A, Vianale G, Orecchia S, Casalini A, Tassi G et al (2001) Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 193(4):468\u2013475","journal-title":"J Pathol"},{"issue":"1","key":"1691_CR22","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s004280050388","volume":"435","author":"JE K\u00f6nig","year":"1999","unstructured":"K\u00f6nig JE, Tolnay E, Wiethege T, M\u00fcller KM (1999) Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma. Virchows Arch Int J Pathol 435(1):8\u201312","journal-title":"Virchows Arch Int J Pathol"},{"issue":"1","key":"1691_CR23","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/sj.bjc.6690650","volume":"81","author":"Y Ohta","year":"1999","unstructured":"Ohta Y, Shridhar V, Bright RK, Kalemkerian GP, Du W, Carbone M et al (1999) VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 81(1):54\u201361","journal-title":"Br J Cancer"},{"issue":"6","key":"1691_CR24","first-page":"686","volume":"32","author":"PH Sugarbaker","year":"2006","unstructured":"Sugarbaker PH, Yan TD, Stuart OA, Yoo D (2006) Comprehensive management of diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 32(6):686\u2013691","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"issue":"6","key":"1691_CR25","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.ejso.2006.03.009","volume":"32","author":"R Garcia-Carbonero","year":"2006","unstructured":"Garcia-Carbonero R, Paz-Ares L (2006) Systemic chemotherapy in the management of malignant peritoneal mesothelioma. Eur J Surg Oncol EJSO 32(6):676\u2013681","journal-title":"Eur J Surg Oncol EJSO"},{"issue":"3","key":"1691_CR26","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/030089160308900307","volume":"89","author":"YIZ Acherman","year":"2003","unstructured":"Acherman YIZ, Welch LS, Bromley CM, Sugarbaker PH (2003) Clinical presentation of peritoneal mesothelioma. Tumori 89(3):269\u2013273","journal-title":"Tumori"},{"issue":"24","key":"1691_CR27","doi-asserted-by":"publisher","first-page":"4560","DOI":"10.1200\/JCO.2003.04.150","volume":"21","author":"AL Feldman","year":"2003","unstructured":"Feldman AL, Libutti SK, Pingpank JF, Bartlett DL, Beresnev TH, Mavroukakis SM et al (2003) Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol 21(24):4560\u20134567","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"6","key":"1691_CR28","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1007\/s004230050246","volume":"384","author":"PH Sugarbaker","year":"1999","unstructured":"Sugarbaker PH (1999) Management of peritoneal-surface malignancy: the surgeon\u2019s role. Langenbecks Arch Surg 384(6):576\u2013587","journal-title":"Langenbecks Arch Surg"},{"issue":"15","key":"1691_CR29","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.3748\/wjg.v16.i15.1901","volume":"16","author":"M-C Ba","year":"2010","unstructured":"Ba M-C, Cui S-Z, Lin S-Q, Tang Y-Q, Wu Y-B, Wang B et al (2010) Chemotherapy with laparoscope-assisted continuous circulatory hyperthermic intraperitoneal perfusion for malignant ascites. World J Gastroenterol 16(15):1901\u20131907","journal-title":"World J Gastroenterol"},{"issue":"1","key":"1691_CR30","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1159\/000338070","volume":"6","author":"L de Mestier","year":"2012","unstructured":"de Mestier L, Volet J, Scaglia E, Msika S, Kianmanesh R, Bouch\u00e9 O (2012) Is palliative laparoscopic hyperthermic intraperitoneal chemotherapy effective in patients with malignant hemorrhagic ascites? Case Rep Gastroenterol 6(1):166\u2013170","journal-title":"Case Rep Gastroenterol"},{"issue":"2","key":"1691_CR31","first-page":"154","volume":"34","author":"E Facchiano","year":"2008","unstructured":"Facchiano E, Scaringi S, Kianmanesh R, Sabate JM, Castel B, Flamant Y et al (2008) Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 34(2):154\u2013158","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"issue":"3","key":"1691_CR32","first-page":"190","volume":"15","author":"A Garofalo","year":"2009","unstructured":"Garofalo A, Valle M (2009) Laparoscopy in the management of peritoneal carcinomatosis: Cancer J 15(3):190\u2013195","journal-title":"Laparoscopy in the management of peritoneal carcinomatosis: Cancer J"},{"issue":"4","key":"1691_CR33","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1097\/SLE.0b013e318173a61e","volume":"18","author":"A Patriti","year":"2008","unstructured":"Patriti A, Cavazzoni E, Graziosi L, Pisciaroli A, Luzi D, Gull\u00e0 N et al (2008) Successful palliation of malignant ascites from peritoneal mesothelioma by laparoscopic intraperitoneal hyperthermic chemotherapy. Surg Laparosc Endosc Percutan Tech 18(4):426\u2013428","journal-title":"Surg Laparosc Endosc Percutan Tech"},{"issue":"5","key":"1691_CR34","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1245\/s10434-013-3224-y","volume":"21","author":"RW Randle","year":"2014","unstructured":"Randle RW, Swett KR, Swords DS, Shen P, Stewart JH, Levine EA et al (2014) Efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the management of malignant ascites. Ann Surg Oncol 21(5):1474\u20131479","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"1691_CR35","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/jso.21321","volume":"100","author":"M Valle","year":"2009","unstructured":"Valle M, Van der Speeten K, Garofalo A (2009) Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: a multi-institutional retrospective analysis in 52 patients. J Surg Oncol 100(4):331\u2013334","journal-title":"J Surg Oncol"},{"issue":"14","key":"1691_CR36","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol Off J Am Soc Clin Oncol 21(14):2636\u20132644","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"2","key":"1691_CR37","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.lungcan.2008.08.013","volume":"64","author":"G Carteni","year":"2009","unstructured":"Carteni G, Manegold C, Garcia GM, Siena S, Zielinski CC, Amadori D et al (2009) Malignant peritoneal mesothelioma\u2014results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer 64(2):211\u2013218","journal-title":"Lung Cancer"},{"issue":"21","key":"1691_CR38","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.1200\/JCO.2007.15.2868","volume":"26","author":"GR Simon","year":"2008","unstructured":"Simon GR, Verschraegen CF, J\u00e4nne PA, Langer CJ, Dowlati A, Gadgeel SM et al (2008) Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol 26(21):3567\u20133572","journal-title":"J Clin Oncol"},{"issue":"65","key":"1691_CR39","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ejca.2016.06.002","volume":"1","author":"V Kepenekian","year":"2016","unstructured":"Kepenekian V, Elias D, Passot G, Mery E, Goere D, Delroeux D et al (2016) Diffuse malignant peritoneal mesothelioma: evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database. Eur J Cancer 1(65):69\u201379","journal-title":"Eur J Cancer"},{"issue":"6","key":"1691_CR40","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1479-5876-6-2","volume":"8","author":"DO Holtz","year":"2008","unstructured":"Holtz DO, Krafty RT, Mohamed-Hadley A, Zhang L, Alagkiozidis I, Leiby B et al (2008) Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer. J Transl Med 8(6):2","journal-title":"J Transl Med"},{"issue":"14","key":"1691_CR41","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12957-016-0892-7","volume":"29","author":"M Robella","year":"2016","unstructured":"Robella M, Vaira M, De Simone M (2016) Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis. World J Surg Oncol 29(14):128","journal-title":"World J Surg Oncol"},{"issue":"2","key":"1691_CR42","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ygyno.2015.02.009","volume":"137","author":"CB Tempfer","year":"2015","unstructured":"Tempfer CB, Winnekendonk G, Solass W, Horvat R, Giger-Pabst U, Zieren J et al (2015) Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: a phase 2 study. Gynecol Oncol 137(2):223\u2013228","journal-title":"Gynecol Oncol"},{"issue":"2","key":"1691_CR43","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s11605-015-2995-9","volume":"20","author":"G Nadiradze","year":"2016","unstructured":"Nadiradze G, Giger-Pabst U, Zieren J, Strumberg D, Solass W, Reymond M-A (2016) Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with low-dose cisplatin and doxorubicin in gastric peritoneal metastasis. J Gastrointest Surg Off J Soc Surg Aliment Tract 20(2):367\u2013373","journal-title":"J Gastrointest Surg Off J Soc Surg Aliment Tract"},{"issue":"4","key":"1691_CR44","first-page":"364","volume":"18","author":"C Demtr\u00f6der","year":"2016","unstructured":"Demtr\u00f6der C, Solass W, Zieren J, Strumberg D, Giger-Pabst U, Reymond M-A (2016) Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis. Colorectal Dis Off J Assoc Coloproctology G B Irel 18(4):364\u2013371","journal-title":"Colorectal Dis Off J Assoc Coloproctology G B Irel"},{"issue":"10","key":"1691_CR45","first-page":"1379","volume":"41","author":"K Odendahl","year":"2015","unstructured":"Odendahl K, Solass W, Demtr\u00f6der C, Giger-Pabst U, Zieren J, Tempfer C et al (2015) Quality of life of patients with end-stage peritoneal metastasis treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC). Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 41(10):1379\u20131385","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"issue":"7","key":"1691_CR46","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1245\/s10434-012-2840-2","volume":"20","author":"A Blanco","year":"2013","unstructured":"Blanco A, Giger-Pabst U, Solass W, Zieren J, Reymond MA (2013) Renal and hepatic toxicities after pressurized intraperitoneal aerosol chemotherapy (PIPAC). Ann Surg Oncol 20(7):2311\u20132316","journal-title":"Ann Surg Oncol"},{"key":"1691_CR47","doi-asserted-by":"crossref","unstructured":"H&#x00FC, Bner M, Teixeira Farinha H, Grass F, Wolfer A, Mathevet P, et al. Feasibility and safety of pressurized intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis: a retrospective cohort study [Internet]. Gastroenterology Research and Practice. 2017 [cited 2017 Oct 3]. Available from: https:\/\/www.hindawi.com\/journals\/grp\/2017\/6852749\/","DOI":"10.1155\/2017\/6852749"}],"container-title":["Indian Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13193-022-01691-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13193-022-01691-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13193-022-01691-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T16:07:40Z","timestamp":1687363660000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13193-022-01691-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,5]]},"references-count":47,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1691"],"URL":"https:\/\/doi.org\/10.1007\/s13193-022-01691-8","relation":{},"ISSN":["0975-7651","0976-6952"],"issn-type":[{"value":"0975-7651","type":"print"},{"value":"0976-6952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,5]]},"assertion":[{"value":"26 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Obtained from all the patients who are a part of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}